C84.Z8 ICD-10-CM Code: Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C84.Z8
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceOther mature T/NK-cell lymphomas, lymph nodes of multiple sites
A type of cancer affecting T-cells or NK-cells (immune system cells) that has spread to lymph nodes in multiple locations throughout the body.

Buddy Insight
Other mature T/NK-cell lymphoma involving multiple lymph node sites reflects widespread dissemination and typically advanced stage disease.
CMS-HCC V28
MappedHCC 20
RAF 1.136
CMS-HCC V24
MappedHCC 10
RAF 0.675
ACA/HHS
MappedHCC 10
Varies by metal level
ESRD/PACE
MappedHCC 10
RAF 0.111
RXHCC
MappedHCC 21
RAF 0.410
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C84.Z8 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C84.Z8 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C84.Z8 in this effective period.
Excludes 1
Official- angioimmunoblastic T-cell lymphoma (C86.50)
- blastic NK-cell lymphoma (C86.40)
- enteropathy-type T-cell lymphoma (C86.20)
- extranodal NK-cell lymphoma, nasal type (C86.00)
- hepatosplenic T-cell lymphoma (C86.10)
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C84.Z8 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C84.Z8 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C84.Z8 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C84.Z8 an HCC code?
Yes. C84.Z8 (Other mature T/NK-cell lymphomas, lymph nodes of multiple sites) maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24), with a community non-dual aged RAF of 1.136. It is billable for payment year 2026.
Coder answer: C84.Z8 is billable and maps to V28 HCC 20, Lung and Other Severe Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C84.Z8
- Description
- Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
- HCC (V28)
- HCC 20 — Lung and Other Severe Cancers
- RAF
- 1.136
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work C84.Z8 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for C84.Z8
For C84.Z8 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C84.Z8 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C84.Z8 is the ICD-10-CM diagnosis code for other mature t/nk-cell lymphomas, lymph nodes of multiple sites. A type of cancer affecting T-cells or NK-cells (immune system cells) that has spread to lymph nodes in multiple locations throughout the body. C84.Z8 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C84.Z8 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 1.136. Under the older CMS-HCC V24 model, C84.Z8 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code when the lymphoma involves multiple lymph node regions and the specific T/NK-cell subtype doesn't fit other C84 categories. Because C84.Z8 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C84.Z8 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code when the lymphoma involves multiple lymph node regions and the specific T/NK-cell subtype doesn't fit other C84 categories
- •Verify documentation specifies multiple sites involvement; if single site, use more specific anatomical code
Clinical Significance
Other mature T/NK-cell lymphoma involving multiple lymph node sites reflects widespread dissemination and typically advanced stage disease. Multi-site involvement is common in aggressive subtypes like angioimmunoblastic T-cell lymphoma, which presents with generalized lymphadenopathy. Capturing multi-site involvement accurately supports appropriate risk stratification and treatment intensity.
Documentation Requirements
- ✓Pathology confirmation of mature T-cell or NK-cell lineage via immunophenotyping (CD3+, CD4/CD8, CD56 for NK-cell)
- ✓Imaging or clinical documentation confirming involvement of lymph nodes of multiple sites
- ✓Specific subtype identification when possible (angioimmunoblastic, hepatosplenic, extranodal NK/T-cell, etc.)
- ✓Ann Arbor staging and whether B-symptoms (fever, night sweats, weight loss) are present
Commonly Confused Codes
- •C84.A series (Cutaneous T-cell lymphoma): C84.Z is for non-cutaneous mature T/NK-cell subtypes; verify the lymphoma is NOT a cutaneous subtype
- •C84.4x (Peripheral T-cell lymphoma, not elsewhere classified): C84.4 is specifically for PTCL-NOS; C84.Z covers other named subtypes not classified elsewhere
- •C86.x (Other specified T/NK-cell lymphomas): Check C86 codes first for hepatosplenic (C86.1), enteropathy-associated (C86.2), or subcutaneous panniculitis-like (C86.3) subtypes

